Xtant Medical (NYSEAMERICAN:XTNT) Shares Cross Above 200 Day Moving Average of $0.00

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.76. Xtant Medical shares last traded at $0.72, with a volume of 74,125 shares traded.

Wall Street Analyst Weigh In

Separately, BTIG Research lifted their price target on Xtant Medical from $2.00 to $3.00 and gave the stock a “buy” rating in a report on Thursday, May 16th.

Xtant Medical Stock Down 4.2 %

The company has a market cap of $93.60 million, a price-to-earnings ratio of -71.85 and a beta of 0.34. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.98 and a current ratio of 2.34.

Xtant Medical (NYSEAMERICAN:XTNT) last issued its quarterly earnings data on Wednesday, May 15th. The medical device company reported ($0.03) earnings per share for the quarter. Xtant Medical had a negative return on equity of 3.60% and a negative net margin of 1.64%. The business had revenue of $27.87 million during the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in Xtant Medical by 3.2% during the first quarter. Vanguard Group Inc. now owns 1,548,312 shares of the medical device company’s stock worth $1,812,000 after purchasing an additional 48,319 shares in the last quarter. AWM Investment Company Inc. purchased a new stake in shares of Xtant Medical in the 3rd quarter valued at $516,000. Finally, Juniper Investment Company LLC acquired a new position in Xtant Medical during the 1st quarter worth about $408,000. Hedge funds and other institutional investors own 69.33% of the company’s stock.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.